Navigation Links
Arena Pharmaceuticals Announces Preliminary Results of Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
Date:12/9/2008

SAN DIEGO, Dec. 9 /PRNewswire-FirstCall/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced preliminary data from a Phase 2b clinical trial of APD125 measuring subjective endpoints in patients with primary insomnia. The initial data analysis indicates that APD125 did not meet the trial's primary or secondary endpoints. Treatment with APD125 was well tolerated, and there were no reports of serious adverse events and no emerging safety findings as compared to placebo. Arena is finishing a complete analysis of the data, but does not anticipate any further development of APD125.

"While we are disappointed and anticipated a different result based on objective polysomnographic results from our previous studies, our priority remains the successful development of lorcaserin, our proprietary investigative treatment for obesity. We expect to announce lorcaserin results from BLOOM, our first pivotal Phase 3 clinical trial, around the end of March and to file a New Drug Application for lorcaserin by the end of 2009," said Jack Lief, Arena's President and Chief Executive Officer. "We look forward to the opportunity to review our lorcaserin program, as well as other programs, at our upcoming R&D Day on December 15."

About Arena Pharmaceuticals

Arena is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs in four major therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. Arena's most advanced drug candidate, lorcaserin, is being investigated in a Phase 3 clinical trial program for the treatment of obesity. Arena's broad pipeline of novel compounds target G protein-coupled receptors, an important class of validated drug targets, and includes compounds being evaluated independently and with partners, including Merck
'/>"/>

SOURCE Arena Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Critical Pharmaceuticals Enter Sustained Release hGH Arena
2. Arena Pharmaceuticals Announces Positive Phase 1b Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis
3. Arena Pharmaceuticals Presented Positive Phase 2a Clinical Trial Results of APD125 for the Treatment of Insomnia at 22nd Annual Meeting of the Associated Professional Sleep Societies
4. Arena Pharmaceuticals, Inc. Announces Initiation of Phase 1 Clinical Trial of Drug Candidate Under Partnership with Taisho Pharmaceutical Co., Ltd.
5. Arena Pharmaceuticals Initiates Phase 2b Clinical Trial of APD125 for the Treatment of Insomnia
6. Arena Pharmaceuticals Announces Positive Phase 1a Clinical Trial Results of APD791 for the Treatment of Arterial Thrombosis and Initiates Phase 1b Clinical Trial
7. Arena Pharmaceuticals Announces APD668 Initial Clinical Study Results Suggest Glucose-Dependent Insulinotropic Receptors May Improve Glucose Control in Patients With Type 2 Diabetes
8. Arena Pharmaceuticals Announces Positive Phase 2 Clinical Trial Results of APD125 for the Treatment of Insomnia
9. Arena Pharmaceuticals to Present at Four Upcoming Investor Conferences
10. Keryx Biopharmaceuticals, Inc. Reports Phase 1/2 Data on KRX-0401 (Perifosine) at 50th Annual Meeting of American Society of Hematology
11. Portola Pharmaceuticals Initiates Phase II Trial of Novel IV and Oral Anti-Platelet Drug in Non-Urgent Percutaneous Coronary Intervention
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... , May 22, 2013 Z-Medica, a ... it has launched the first-ever line of products designed ... The line includes QuikClot ® EMS 4x4 Dressing, ... ® EMS Rolled Gauze™, all custom-designed to help ... they can be transported to a hospital or trauma ...
(Date:5/22/2013)... 22, 2013  MGT Capital Investments, Inc. (NYSE MKT: ... the Second Annual Marcum LLP MicroCap Conference on Thursday, ... at the Grand Hyatt Hotel.  ... will update investors and answer questions. (Logo: ... is scheduled to begin at 9:30 a.m. EDT.  MGT,s ...
(Date:5/22/2013)... , May 22, 2013 Hemoglobin A1C ... patients with Type 2 diabetes, while modest improvements ... health outcomes and can lead to substantial healthcare ... the International Society for Pharmacoeconomics and Outcomes Research ... two studies, sponsored by Valeritas, makers of the ...
Breaking Medicine Technology:Z-Medica Launches New Line of Hemostatic Agents for use in Emergency Medical Services 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 3MGT Capital Investments, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 2Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 3Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 4Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 5Type 2 Diabetes Control Worsening, According To Study Of Patients On Commercial Insurance 6
... 21, 2011  BARRX Medical Inc., a leader in developing ... to remove precancerous tissue from the gastrointestinal tract, announces ... be acquired by Covidien.  Covidien is a leading global ... advanced energy-based devices.  Covidien will acquire ...
... NORRITON, Pa., Nov. 21, 2011 Tengion, Inc. (NASDAQ: ... today announced that Brian Davis, Vice President Finance and ... upcoming Piper Jaffray 23rd Annual Health Care Conference on ... A live audio webcast of the presentation ...
Cached Medicine Technology:BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 2BARRX Medical, Inc. Announces Definitive Agreement to be Acquired by Covidien 3Tengion to Present at Piper Jaffray 23rd Annual Health Care Conference 2
(Date:5/22/2013)... 22, 2013 Today, Zane Benefits, Inc. ... Insurance Exchange . Zane Benefits, which provides comprehensive and ... the leader in defined contribution plans and ... Benefits’ website, beginning in 2014 as part of the ... and small businesses will become available through new state ...
(Date:5/22/2013)... Hopkins researchers report that hospitals may be reaping ... complicated by preventable bloodstream infections contracted in their ... study, reported online in the American Journal ... an ICU patient who develops an avoidable central ... more to care for than a similar infection-free ...
(Date:5/22/2013)... 22, 2013 Registered Dietitian and Founder of ... on Tatalou.com sharing a recipe for making energy bars at ... Energy Bars ,” takes a recipe modified from one ... , “Every day it gets more and more difficult to ... Chevreau. “The size of the nutrition label continues to grow ...
(Date:5/22/2013)... Unknown to the citizens of Wichita, Kansas a tornado was ... it struck, the city’s warning siren started blaring and informed ... to reach safety and prevented any deaths or injuries. ... product that will increase safety in the workplace if a ... System provides employees with the same type of warning ...
(Date:5/22/2013)... (HealthDay News) -- People with heart failure are more ... gland that is even mildly underactive, according to a ... researchers found an increased risk of death linked to ... "This study is the first to show that African-Americans ... than patients of other racial and ethnic groups," Dr. ...
Breaking Medicine News(10 mins):Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 2Health News:Zane Benefits Publishes New Information on Alabama Health Insurance Exchange 3Health News:Hospitals profit when patients develop bloodstream infections 2Health News:Hospitals profit when patients develop bloodstream infections 3Health News:Hospitals profit when patients develop bloodstream infections 4Health News:How To "Make Your Own Healthy Energy Bars" 2Health News:Telcom & Data Introduces Wheelock SAFEPATH® SP40S Emergency Evacuation System, An Effective Office Tool to Protect Employees from Severe Weather Threats 2Health News:Underactive Thyroid and Heart Failure a Bad Combination: Study 2
... BOARD,S INTERESTS ARE NOT ALIGNED WITH STOCKHOLDERSADVOCAT BOARD NEEDS ... Calif., May 19 Bristol Investment Fund, Ltd. ("Bristol") ... the stockholders of Advocat, Inc. (the "Company") (Nasdaq: ... highly qualified and independent director nominees, Paul Kessler and ...
... microsite (www.meettheburns.com) targets first time athlete,s foot sufferers ... Schering-Plough Corporation (NYSE: SGP ... an antifungal spray for the treatment of athlete,s ... liquid spray and deodorant powder spray.(Photo: ...
... Sustainable Healthcare CHICAGO, May 19 Practice ... to environmentally responsible healthcare, has announced its ... competitive awards are given to institutions within ... reduce the facility,s environmental footprint.Fletcher Allen Health ...
... differ across continents, posing challenges to drug launches. ... regulatory environment of the European Union (EU) and ... less price controlled markets witness quicker launches, while ... industry, along with regulatory agencies, has been working ...
... 2009 The International Diabetes Federation (IDF), International ... (WHF) today issued a joint statement that calls ... epidemic of non-communicable diseases (NCDs), responsible for 35 ... substantial increase in funding for NCDs and greater ...
... in the Los Angeles , California area will be ... describe a revolutionary laser liposuction procedure. Dr. ... Center is one of the first surgeons on ... laser liposuction technique -- that not only melts fat, ...
Cached Medicine News:Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 2Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 3Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 4Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 5Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 6Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 7Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 8Health News:Support Bristol's Highly Qualified Independent Nominees for Advocat Board 9Health News:Video: Schering-Plough Introduces TINACTIN(R) CHILL, a Line of Antifungal Products Geared Specifically to Young Males 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 2Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 3Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 4Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 5Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 6Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 7Health News:Practice Greenhealth Announces Winners of 2009 Environmental Excellence Awards 8Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 2Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 3Health News:Transatlantic Regulatory Integration of Drug Approval Process Vital for the Global Pharmaceutical Industry, Notes Frost & Sullivan 4Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 2Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 3Health News:Leading NGOs call for international action to combat epidemic of noncommunicable diseases 4Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 2Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 3Health News:Los Angeles Cosmetic Plastic Surgeon Dr. Christine Petti and Smartlipo Featured on Upcoming Episode of The Doctors 4
The Diamedix immunosimplicity® Is- Rheumatoid Factor Test Kit is an EIA procedure intended for the quantitation of IgM antibodies to IgG antigen. The results are reported in IU/mL, traceable to t...
... The SYNCHRON CX4 Delta Specialty / ... access analyzer that can consolidate Drugs ... testing, such as thyroid, HbA1c and ... CX4 Delta offers a level of ...
Inquire...
... Analyzer is a high precision optical system ... of the anterior eye segment, based on ... a Placido Disk. , GALILEI combines the ... high accuracy curvature data, while Scheimpflug imaging ...
Medicine Products: